BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
25
Data completeness
6/8 — Strong
Priority Review
CYRAMZA (ramucirumab) by Eli Lilly and Company is vegfr2 inhibitors [moa]. Approved for vascular endothelial growth factor receptor 2 antagonist [epc]. First approved in 2014.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYRAMZA (ramucirumab) is a monoclonal antibody targeting VEGFR2, a key driver of tumor angiogenesis. It is approved for multiple solid tumors including gastric cancer, non-small cell lung cancer, colorectal cancer, and hepatocellular carcinoma. The drug works by blocking vascular endothelial growth factor receptor 2 to inhibit new blood vessel formation that feeds tumors.
$0.004BPart D
PeakProduct is at peak lifecycle maturity with established market presence; team focus likely on market maintenance and indication expansion rather than growth acceleration.
Mechanism of Action
VEGFR2 Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Receptor 2 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (25)
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
Started Apr 2024
168 enrolled
Gastroesophageal Adenocarcinoma
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
Started Oct 2023
37 enrolled
Recurrent Head and Neck CancerRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Carcinoma+3 more
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Started Aug 2023
56 enrolled
Non Small Cell Lung CancerMetastaticRecurrent
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
Started Mar 2023
838 enrolled
Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer
Started Nov 2021
35 enrolled
Adenocarcinoma GastricGastrooesophageal Cancer
Worked on CYRAMZA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.